Germany· DE-A57-8c71dfde12045416
Lapatinib Stada
A lapatinib product containing lapatinib, registered in Germany by Stadapharm Gmbh. The same ATC class is registered in 12 of our 19 countries.
Checked against EMA Article 57 (European Union) on
Informational only — not a medical device.
Where it is registered
Lapatinib is registered in 12 of 19 countries.
Countries holding a registration under ATC L01EH01 (lapatinib), each read from that country’s own register.
- This record: Germany, from EMA Article 57 (European Union)
- 6 of them publish a price we can compare per daily dose
Lapatinib · ATC L01EH01
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of lapatinib costs, country by country.
Normalised to the WHO defined daily dose (1.25 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Lapatinib · price per daily dose (1.25 g)
USD · FX 28 Sept 2026
- CH Switzerland$101.12
The record
At a glance
EMA Article 57 (European Union)- Active substance
- Lapatinib
- Manufacturer
- Stadapharm Gmbh
- Country
- Germany (DE)
- ATC code
- L01EH01
- ATC class
- Lapatinib
- Defined daily dose
- 1.25 g, O
- Reimbursed
- Not published by this register
- Source register
- EMA Article 57 (European Union)
- Last checked
- September 30, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
675 interactions on record for lapatinib.
Graded by severity as the source publishes them — 124 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lapatinib · interactions on record
675 records
- 124 severe
- 537 moderate
- 14 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- LoperamideA07DA03severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Lapatinib in 6 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainLAPATINIB STADA 250 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGLaboratorio Stada S.L.
- SwitzerlandTyverb, FilmtablettenNovartis Pharma Schweiz AG
- PolandBrastibSTADA Arzneimittel AG
- SwedenLapatinib Newbury 250 mg Filmdragerad tablettNewbury Pharmaceuticals AB
- CanadaTYKERBNOVARTIS PHARMACEUTICALS CANADA INC
- United KingdomTyverb 250mg tabletsNovartis Pharmaceuticals UK Ltd
Authorised across Europe · EMA
The same active substance is authorised in 13 EEA countries. Names it is sold under:
- Cyprus · Laprem
- Denmark · Lapatinib Newbury
- Spain · Lapatinib Stada
- France · Lapatinib Pharos
- Iceland · Lapatinib Newbury, Tyverb
- Liechtenstein · Tyverb
- Malta · Lapatinib Pharos
- Netherlands · Brastib, Lapatinib Pharos
- Norway · Tyverb
- Poland · Brastib
- Romania · Lapatinib Stada
- Sweden · Lapatinib Newbury
- Slovakia · Lapatinib Stada
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/dd50cbb6-ec27-4d68-a773-8a9374cd7c9e GET /v1/drugs/dd50cbb6-ec27-4d68-a773-8a9374cd7c9e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"pzn": null,
"route": "Oral Use",
"source": "ema_art57_de",
"ma_number": null,
"substance": "Lapatinib",
"atc_from_source": null,
"authorisation_country": "Germany"
}See everything about lapatinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.